Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a note issued to investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their price objective on shares of Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th.

Aptose Biosciences Stock Performance

APTO stock opened at $0.18 on Friday. The firm has a market cap of $3.24 million, a price-to-earnings ratio of -0.06 and a beta of 1.26. The firm has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.58. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.91.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.